Anesthesiology and Pain Medicine

Published by: Kowsar

Efficacy of Botulinum Toxin Type A for Treating Chronic Low Back Pain

Seyed M. Jazayeri 1 , Alireza Ashraf 1 , Habib M. Fini 1 , Hajar Karimian 1 , * and Mohamadreza V. Nasab 2
Authors Information
1 Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Physical Medicine and Rehabilitation, Shahid Sadughi University of Medical Sciences, Yazd, Iran
Article information
  • Anesthesiology and Pain Medicine: September 23, 2011, 1 (2); 77-80
  • Published Online: September 26, 2011
  • Article Type: Research Article
  • Received: July 8, 2011
  • Revised: August 25, 2011
  • Accepted: August 30, 2011
  • DOI: 10.5812/kowsar.22287523.1845

To Cite: Jazayeri S M, Ashraf A, Fini H M, Karimian H, Nasab M V. Efficacy of Botulinum Toxin Type A for Treating Chronic Low Back Pain, Anesth Pain Med. 2011 ; 1(2):77-80. doi: 10.5812/kowsar.22287523.1845.

Copyright © 2011, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008; 8(1): 8-20[DOI][PubMed]
  • 2. National Institute of Neurological Disordersand Stroke. Low Back Pain Fact Sheet.;
  • 3. Tamcan O, Mannion AF, Eisenring C, Horisberger B, Elfering A, Muller U. The course of chronic and recurrent low back pain in the general population. Pain. 2010; 150(3): 451-7[DOI][PubMed]
  • 4. Foster NE, Thomas E, Bishop A, Dunn KM, Main CJ. Distinctiveness of psychological obstacles to recovery in low back pain patients in primary care. Pain. 2010; 148(3): 398-406[DOI][PubMed]
  • 5. Mason VL, Skevington SM, Osborn M. Assessing the properties of the WHOQOL-Pain: quality of life of chronic low back pain patients during treatment. Clin J Pain. 2010; 26(7): 583-92[DOI][PubMed]
  • 6. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C. Withdrawn: Multidisciplinary bio-psycho-social rehabilitation for chronic low-back pain. Cochrane Database Syst Rev. 2006; 18(2)
  • 7. Brin MF. Basic and clinical aspects of BOTOX. Toxicon. 2009; 54(5): 676-82[DOI][PubMed]
  • 8. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006; 9(2-3): 145-8[DOI][PubMed]
  • 9. Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010; 33(1): 22-6[PubMed]
  • 10. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56(11): 1523-8[DOI][PubMed]
  • 11. Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007; 7(6): 637-47[DOI][PubMed]
  • 12. Molenaers G, Schorkhuber V, Fagard K, Van Campenhout A, De Cat J, Pauwels P, et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol. 2009; 13(5): 421-9[DOI][PubMed]
  • 13. Ong LC, Wong SW, Hamid HA. Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of Botulinum Toxin A. J Pediatr Neurol. 2009; 7(2): 141-5
  • 14. Seifart A, Unger M, Burger M. Functional electrical stimulation to lower limb muscles after botox in children with cerebral palsy. Pediatr Phys Ther. 2010; 22(2): 199-206[DOI][PubMed]
  • 15. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008; 89(5): 799-806[DOI][PubMed]
  • 16. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008; 115(4): 617-23[DOI][PubMed]
  • 17. Jost WH. Botulinum toxin in multiple sclerosis. J Neurol. 2006; 253-20[DOI][PubMed]
  • 18. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010; 184(3): 1011-6[DOI][PubMed]
  • 19. Schapiro RT. Managing the symptoms of multiple sclerosis. 2007;
  • 20. Bahman J. Botulinum toxin treatment of low back pain and fibromyalgia. Toxicon. 2008; 51: 48[DOI]
  • 21. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001; 56(10): 1290-3[DOI][PubMed]
  • 22. Jabbari B. Treatment of chronic low back pain with botulinum neurotoxins. Curr Pain Headache Rep. 2007; 11(5): 352-8[DOI][PubMed]
  • 23. Nagarajan V, Al-Shubaili A, Ayad YM, Alexander J, Al-Ramezi K. Low back ache treatment with botulinum neurotoxin type A. Local experience in Kuwait. Med Princ Pract. 2007; 16(3): 181-6[DOI][PubMed]
  • 24. Ney JP, Difazio M, Sichani A, Monacci W, Foster L, Jabbari B. Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients. Clin J Pain. 2006; 22(4): 363-9[DOI][PubMed]
  • 25. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983; 17(1): 45-56[DOI]
  • 26. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980; 66(8): 271-3[PubMed]
  • 27. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain. 1994; 56(2): 217-26[DOI]
  • 28. Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006; 7(3): 260-4[DOI][PubMed]
  • 29. Subin B, Saleemi S, Morgan G, Zavisca F, Cork R. Treatment of Chronic Low Back Pain by Local Injection of Botulinum Toxin-A. Internet J Pain, Symptom Control and Palliat Care. 2003; 2(2)
  • 30. Dressler D. Botulinum toxin mechanisms of action. Suppl Clin Neurophysiol. 2004; 57: 159-66[DOI]
  • 31. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008; 64(3): 274-83[DOI][PubMed]
  • 32. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38(2): 245-58[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments